Global Avascular Necrosis Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Type;

Trauma Related Avascular Necrosis (AVN) and Non-Trauma Related Avascular Necrosis (AVN).

By Site;

Hip Bone, Knee, and Shoulder.

By Diagnosis;

Imaging and Biopsy.

By End User;

Hospitals & Clinics, Diagnostic Centers, and Ambulatory Surgical Centers.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn568450981 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Avascular Necrosis Market (USD Million), 2021 - 2031

In the year 2024, the Global Avascular Necrosis Market was valued at USD 781.46 million. The size of this market is expected to increase to USD 1,190.63 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.2%.

Avascular necrosis (AVN), also known as osteonecrosis, is a condition characterized by the death of bone tissue due to a lack of blood supply. This interruption in blood flow can lead to the collapse of the affected bone and ultimately joint destruction. AVN primarily affects the hip, knee, shoulder, and ankle joints, though it can occur in other bones as well. The exact cause of AVN can vary and may include trauma, chronic corticosteroid use, excessive alcohol consumption, blood disorders, and certain medical treatments like radiation therapy.

The global market for avascular necrosis is driven by a growing awareness of the condition and advances in diagnostic techniques. Early detection is crucial as it can significantly impact treatment outcomes and patient prognosis. Diagnostic tools such as MRI scans and bone scans play a vital role in identifying AVN in its early stages, enabling timely intervention to preserve joint function and prevent further deterioration.

Treatment options for AVN range from conservative management to surgical interventions, depending on the stage and severity of the disease. Non-surgical approaches include rest, physical therapy, medications to reduce pain and inflammation, and lifestyle modifications such as weight management and reducing alcohol consumption. Surgical interventions may involve core decompression, bone grafting, osteotomy, or joint replacement, aimed at relieving symptoms, preserving joint function, and improving quality of life.

The global market landscape for AVN therapies is witnessing significant research and development efforts aimed at developing innovative treatment modalities. Biopharmaceutical companies, medical device manufacturers, and research institutions are actively engaged in clinical trials and studies to explore new therapeutic avenues. These efforts are aimed not only at improving treatment efficacy but also at addressing the underlying causes of AVN to prevent disease progression and reduce the need for invasive interventions.

In conclusion, the global market for avascular necrosis is characterized by a complex interplay of diagnostic advancements, therapeutic innovations, and ongoing research. As understanding of the condition deepens and treatment options evolve, the outlook for patients diagnosed with AVN continues to improve, offering hope for better outcomes and enhanced quality of life.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Site
    3. Market Snapshot, By Diagnosis
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Global Avascular Necrosis Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Demand growth

        2. Rehabilitation Programs

        3. Market expansion

        4. Improved Surgical Precision

      2. Restraints
        1. High initial investment

        2. Regulatory hurdles

        3. Supply chain disruptions

        4. Competitive pressures

      3. Opportunities
        1. Sustainability trends

        2. Strategic partnerships

        3. Consumer awareness

        4. Product diversification

    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Avascular Necrosis Market, By Type, 2021 - 2031 (USD Million)
      1. Trauma Related Avascular Necrosis (AVN)
      2. Non-Trauma Related Avascular Necrosis (AVN)
    2. Global Avascular Necrosis Market, By Site, 2021 - 2031 (USD Million)
      1. Hip Bone
      2. Knee
      3. Shoulder
    3. Global Avascular Necrosis Market, By Diagnosis, 2021 - 2031 (USD Million)
      1. Imaging
      2. Biopsy
    4. Global Avascular Necrosis Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals & Clinics
      2. Diagnostic Centers
      3. Ambulatory Surgical Centers
    5. Global Avascular Necrosis Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea ASEAN (Association of South East Asian Countries)
        6. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Sanofi
      2. Bayer Healthcare AG
      3. Boehringer Ingelheim GmbH
      4. Pfizer Inc.
      5. Merck KGaA
      6. Stryker Corporation
      7. Medtronic PLC
      8. Aurobindo Pharma
      9. Integra LifeSciences Corporation
      10. Zimmer Biomet Holdings
      11. Wright Medical Group N.V.
      12. Grifols SA
      13. Smith & Nephew
      14. Ethicon Inc.
  7. Analyst Views
  8. Future Outlook of the Market